Coherus Oncology, Inc.
CHRS
$1.22
$0.065.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -230.49% | -- | -154.99% | 36.35% | 72.88% |
| Total Depreciation and Amortization | -37.64% | -- | -30.59% | -2.82% | 72.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | 72.79% | -- |
| Total Other Non-Cash Items | -127.36% | -- | 113.48% | -65.59% | -27.74% |
| Change in Net Operating Assets | 84.74% | -- | 195.44% | 756.30% | -122.77% |
| Cash from Operations | 25.28% | -- | 44.78% | 321.13% | -14.21% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15,241.22% | -- | -108.62% | -101.54% | -98.98% |
| Cash from Investing | -15,241.22% | -- | -108.62% | -101.54% | -99.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -72.95% | -100.00% |
| Repurchase of Common Stock | 70.00% | -- | 64.56% | 96.93% | 94.29% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 131.25% | -- | -- | 100.00% | 92.38% |
| Cash from Financing | 101.20% | -- | -129.76% | -36.89% | -101.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -83.94% | -- | -127.78% | 25.03% | -939.87% |